Rayonier Advanced Materials (RYAM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Mar, 2026Executive summary
2025 financial performance was below expectations, with significant losses and negative cash flow; restoring profitability and cash generation is a top priority for 2026.
The Board intensified oversight of operations, cost discipline, and capital allocation, and expects measurable improvements in 2026.
Leadership transition occurred, with Scott M. Sutton appointed as President and CEO in January 2026, emphasizing operational discipline and capital allocation.
Management's focus areas include restoring free cash flow, strengthening competitive positioning, improving reliability, and maintaining disciplined capital spending.
Voting matters and shareholder proposals
Election of three Class III directors for terms expiring in 2029.
Proposal to declassify the Board of Directors, moving to annual elections over a three-year phase-in.
Proposal to eliminate supermajority voting provisions, reducing required approval thresholds to a simple majority.
Advisory vote on executive compensation (Say-on-Pay).
Approval of a French Sub-Plan under the 2023 Incentive Stock Plan for tax-advantaged equity awards to French employees.
Ratification of Grant Thornton LLP as independent auditor for 2026.
Board of directors and corporate governance
Board consists of nine directors, 89% of whom are independent; three are women and one is racially/ethnically diverse.
Board refreshment since 2022 resulted in five new directors (56% refreshment), with an average tenure of six years.
Annual management succession planning and structured onboarding for new directors.
Independent Chair role separated from CEO; Lisa M. Palumbo serves as Chair.
Board committees include Audit, Compensation and Management Development, Nominating and Corporate Governance, and Sustainability (to be integrated into the full Board in 2026).
Directors are subject to stock ownership and retention requirements, and annual limits on compensation.
Latest events from Rayonier Advanced Materials
- 2026 targets positive cash flow, EBITDA growth, and new product launches amid disciplined execution.RYAM
Gabelli Funds Annual Specialty Chemicals Symposium20 Mar 2026 - 2025 results showed lower revenue and EBITDA, with 2026 targeting free cash flow recovery.RYAM
Q4 20254 Mar 2026 - Aiming to double EBITDA by 2027, leveraging price, cost, and biomaterials growth.RYAM
17th Annual Southwest IDEAS Conference3 Feb 2026 - Transformation to specialty cellulose, innovation, and sustainability drive growth and profitability.RYAM
Fireside Chat3 Feb 2026 - Shifting to specialty cellulose and biomaterials, with debt reduction and margin expansion in focus.RYAM
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 net sales and earnings surged, with 2024 guidance raised and cash flow outlook improved.RYAM
Q2 20242 Feb 2026 - Shifting to specialty cellulose and biomaterials, with asset sales and debt reduction underway.RYAM
Stifel 2024 Cross Sector Insight Conference1 Feb 2026 - Q3 net sales and Adjusted EBITDA surged, 2024 guidance held, and $700M refinancing secured.RYAM
Q3 202416 Jan 2026 - Focus on specialty cellulose, biomaterials, and debt reduction drives margin and cash flow growth.RYAM
Gabelli Funds' 16th Annual Specialty Chemicals Symposium26 Dec 2025